EcoDrugPlus

Integrin Subunit Beta 1

Ensembl ID : ENSSDUG00000003862
Gene Symbol: ITGB1
3 Cross references
213 Possible Orthologues:

Integrin Subunit Beta 3

Ensembl ID : ENSSDUG00000021710
Gene Symbol: ITGB3
3 Cross references
194 Possible Orthologues:

Integrin Subunit Beta 5

Ensembl ID : ENSSDUG00000015939
Gene Symbol: ITGB5
3 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSSDUG00000020655
Gene Symbol: ITGB6
3 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSSDUG00000007115
Gene Symbol: ITGB8
3 Cross references
202 Possible Orthologues:

Integrin, Alpha 2b

Ensembl ID : ENSSDUG00000023709
Gene Symbol: ITGA2B
1 Cross references
190 Possible Orthologues:

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSSDUG00000023039
Gene Symbol: IRAK4
3 Cross references
202 Possible Orthologues:

Interleukin-8-Like

Ensembl ID : ENSSDUG00000022252
Gene Symbol: LOC111231462
3 Cross references
183 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSSDUG00000017961
Gene Symbol: IDH1
3 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSSDUG00000011097
Gene Symbol: IDH2
3 Cross references
206 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSSDUG00000011184
Gene Symbol: IDH2
1 Cross references
206 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp], Mitochondrial-Like

Ensembl ID : ENSSDUG00000004104
Gene Symbol: LOC111218048
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).